Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

SHA:688336 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	246.11	459.49	933.26	1,091	1,614	1,778
Short-Term Investments	444.54	863.59	344.19	-	-	50
Trading Asset Securities	1,033	910.54	603.87	1,486	752.05	932.63
Cash & Short-Term Investments	1,724	2,234	1,881	2,577	2,366	2,761
Cash Growth	30.78%	18.73%	-27.00%	8.93%	-14.31%	141.69%
Accounts Receivable	369.36	147.14	133.24	149.35	256.97	102.92
Other Receivables	0.35	0.03	0.2	0.29	0.53	0.5
Receivables	369.7	147.17	133.44	149.65	257.5	103.42
Inventory	243.56	229.6	194.96	227	210.14	225.08
Other Current Assets	3,523	49.64	40.09	32.54	38.09	32.3
Total Current Assets	5,860	2,660	2,250	2,986	2,872	3,122
Property, Plant & Equipment	1,525	1,539	1,562	1,426	1,371	1,287
Long-Term Investments	31.55	1,140	1,020	109.4	122.37	105.59
Goodwill	0.64	0.64	0.64	0.64	0.64	0.64
Other Intangible Assets	212.83	223.96	240.16	195.73	196.55	221.17
Long-Term Deferred Tax Assets	105.78	129.62	145.74	173.43	155.31	103.18
Long-Term Deferred Charges	296.27	228.54	44.44	114.02	97.67	79.48
Other Long-Term Assets	779.49	43.68	42.16	92.76	73.59	35.53
Total Assets	8,811	5,965	5,305	5,098	4,889	4,954
Accounts Payable	46.14	34.96	21.93	15.91	16.27	21.36
Accrued Expenses	45.77	174.93	181.2	56.18	127.71	177.5
Short-Term Debt	-	50.02	50.03	150.1	-	-
Current Income Taxes Payable	7.18	1.3	1.3	1.2	0.21	0.21
Current Unearned Revenue	2,606	20.2	16.77	19.55	3.25	15.42
Other Current Liabilities	147.13	35.49	36.91	132.15	68.01	65.83
Total Current Liabilities	2,852	316.91	308.14	375.09	215.45	280.32
Long-Term Unearned Revenue	99.86	111.24	118.33	123.79	134.28	153.11
Total Liabilities	2,952	428.15	426.47	498.88	349.73	433.44
Common Stock	616.79	616.79	616.79	616.79	616.21	616.21
Additional Paid-In Capital	2,329	2,310	2,303	2,309	2,301	2,273
Retained Earnings	2,962	2,639	1,985	1,691	1,641	1,623
Comprehensive Income & Other	-8.4	2.44	-8.71	-10.67	-17.33	-9.68
Total Common Equity	5,899	5,568	4,896	4,606	4,542	4,503
Minority Interest	-39.92	-30.76	-17.58	-6.32	-2.46	17.29
Shareholders' Equity	5,859	5,537	4,879	4,600	4,539	4,520
Total Liabilities & Equity	8,811	5,965	5,305	5,098	4,889	4,954
Total Debt	-	50.02	50.03	150.1	-	-
Net Cash (Debt)	1,724	2,184	1,831	2,427	2,366	2,761
Net Cash Growth	35.94%	19.24%	-24.55%	2.59%	-14.31%	141.69%
Net Cash Per Share	2.76	3.53	2.98	3.94	3.93	4.70
Filing Date Shares Outstanding	616.79	616.79	616.79	616.79	616.21	616.21
Total Common Shares Outstanding	616.79	616.79	616.79	616.79	616.21	616.21
Working Capital	3,008	2,343	1,942	2,611	2,656	2,841
Book Value Per Share	9.56	9.03	7.94	7.47	7.37	7.31
Tangible Book Value	5,685	5,343	4,655	4,409	4,344	4,281
Tangible Book Value Per Share	9.22	8.66	7.55	7.15	7.05	6.95
Buildings	-	626.77	626.77	531.48	531.48	516.17
Machinery	-	1,220	1,196	1,043	1,035	1,007
Construction In Progress	-	749.65	687.81	717.11	572.47	434.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.